RE:Neuramedy dealNot enough public information, OB, is a weakness of the press release and everything Bioasis does these days. Yes, this might be an excellent deal, but that also serves as a very modest appraisal of Neuramedy and its drug.
Maybe tomorrow I'll put some more attractive assessments together, to ameliorate the chagrin caused by more objective assessments.
You know, it's up to Bioasis to assess the value of drug/disease combinations. That is the business in which Bioasis finds itself, and it is the business that Bioasis should have known it would have, given that the company did not and now cannot work on its own pipeline.
jd